Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month ...
Morning Overview on MSN
Ultra-processed foods tracked to slower thinking even in people who otherwise eat well
Adults who eat more ultra-processed foods show measurably slower thinking on standardized cognitive tests, and the effect persists even when their broader diet scores well on established ...
Regular moderate to high intensity aerobic exercise may help preserve physical function in early-stage Parkinson disease, according to a cross-sectional study comparing active and low-active ...
There is an inseparable relationship between cognitive decline and cardiovascular disease. In particular, there is a close connection with cerebrovascular disease, and it is a well-known fact that ...
Background High-efficacy disease-modifying therapies (HETs) have substantially improved multiple sclerosis (MS) management, yet ongoing cognitive decline remains a concern. This study aims to assess ...
Introduction Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet ...
Through its patient-data-derived Gemini digital twins, Aitia is uncovering the hidden genetic and molecular mechanisms that causally drive human disease, and accelerating the discovery of breakthrough ...
On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...
bDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark cDepartment of Neurology and Center of Clinical Neuroscience, First Faculty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results